Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody- mediated apoptosis

Masahiko Takahashi, Hidetsugu Saito, Torayuki Okuyama, Toshiyuki Miyashita, Motomichi Kosuga, Futoshi Sumisa, Masao Yamada, Hirotoshi Ebinuma, Hiromasa Ishii

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background/Aims: Fas is a cell surface antigen, that triggers apoptosis upon specific ligand or antibody binding. The proto-oncogene bcl-2 prevents apoptosis induced by various treatments. The aim of our study was to evaluate whether Bcl-2 protects hepatoma cells from Fas-mediated apoptosis. Methods: Two human cell lines, HCC-T and HepG2 were used. Expression of Fas antigen and Bcl-2 was detected by flow cytometry and Western blotting. Cell viability and apoptotic change were examined after anti-Fas- and antisense oligodeoxynucleotide treatments. Apoptotic cells were detected by nick-end labelling and the TUNEL method. To test if Bcl-2 expression can protect HepG2 cells from Fas-mediated apoptosis, the cells were transduced using retroviral vector, LZBC, designed to coexpress E. coli β-galactosidase and human Bcl- 2. To further confirm the protective effect of Bcl-2 expression against Fas- mediated apoptosis in HepG2, Bcl-2 expressing plasmid vector was produced and a cell line stably expressing Bcl-2 was cloned. Results: Western blot analysis showed constitutive Bcl-2 expression in HCC-T cells, but not in HepG2 cells. HCC-T was resistant to apoptosis after treatment with an agonist anti-Fas antibody (1 μg/ml for 3 days), whereas 33% of the HepG2 cells were killed by this treatment. Inhibition of Bcl-2 expression by transfection of antisense oligodeoxynucleotides caused spontaneous apoptosis in HCC-T, but not in HepG2 cells, suggesting that Bcl-2 is essential for survival of HCC-T cells, whereas other proteins may substitute for it in HepG2 cells. Following LZBC infection, 10% HepG2 cells were β-galactosidase-positive by X-gal staining and Bcl-2-positive. In cells surviving after anti-Fas treatment, the proportion of β-galactosidase-positive cells increased to 50% and the β- galactosidase activity increased 6-fold, indicating that Bcl-2 expression protected the cells from Fas-mediated apoptosis. In the cloned HepG2 cells stably expressing Bcl-2, the extent of Fas-mediated apoptosis was inversely related to the level of Bcl-2 expression. Conclusion: Bcl-2 confers protection to human hepatoma cells against Fas-mediated apoptosis, and is essential for survival of some, but not all, hepatoma cells.

Original languageEnglish
Pages (from-to)315-322
Number of pages8
JournalJournal of Hepatology
Volume31
Issue number2
DOIs
Publication statusPublished - 1999 Aug

Fingerprint

Hepatocellular Carcinoma
Hep G2 Cells
Apoptosis
Antibodies
Galactosidases
Oligodeoxyribonucleotides
Western Blotting
CD95 Antigens
T-Lymphocytes
Cell Line
Survival
Proto-Oncogenes
In Situ Nick-End Labeling
Surface Antigens
Transfection
Anti-Idiotypic Antibodies
Cell Survival
Flow Cytometry
Plasmids
Staining and Labeling

Keywords

  • Antisense oligonucleotide
  • Gene transfer
  • Human hepatoma cell line

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody- mediated apoptosis. / Takahashi, Masahiko; Saito, Hidetsugu; Okuyama, Torayuki; Miyashita, Toshiyuki; Kosuga, Motomichi; Sumisa, Futoshi; Yamada, Masao; Ebinuma, Hirotoshi; Ishii, Hiromasa.

In: Journal of Hepatology, Vol. 31, No. 2, 08.1999, p. 315-322.

Research output: Contribution to journalArticle

Takahashi, M, Saito, H, Okuyama, T, Miyashita, T, Kosuga, M, Sumisa, F, Yamada, M, Ebinuma, H & Ishii, H 1999, 'Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody- mediated apoptosis', Journal of Hepatology, vol. 31, no. 2, pp. 315-322. https://doi.org/10.1016/S0168-8278(99)80230-X
Takahashi, Masahiko ; Saito, Hidetsugu ; Okuyama, Torayuki ; Miyashita, Toshiyuki ; Kosuga, Motomichi ; Sumisa, Futoshi ; Yamada, Masao ; Ebinuma, Hirotoshi ; Ishii, Hiromasa. / Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody- mediated apoptosis. In: Journal of Hepatology. 1999 ; Vol. 31, No. 2. pp. 315-322.
@article{25fa83444534496387af4c1f6987a307,
title = "Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody- mediated apoptosis",
abstract = "Background/Aims: Fas is a cell surface antigen, that triggers apoptosis upon specific ligand or antibody binding. The proto-oncogene bcl-2 prevents apoptosis induced by various treatments. The aim of our study was to evaluate whether Bcl-2 protects hepatoma cells from Fas-mediated apoptosis. Methods: Two human cell lines, HCC-T and HepG2 were used. Expression of Fas antigen and Bcl-2 was detected by flow cytometry and Western blotting. Cell viability and apoptotic change were examined after anti-Fas- and antisense oligodeoxynucleotide treatments. Apoptotic cells were detected by nick-end labelling and the TUNEL method. To test if Bcl-2 expression can protect HepG2 cells from Fas-mediated apoptosis, the cells were transduced using retroviral vector, LZBC, designed to coexpress E. coli β-galactosidase and human Bcl- 2. To further confirm the protective effect of Bcl-2 expression against Fas- mediated apoptosis in HepG2, Bcl-2 expressing plasmid vector was produced and a cell line stably expressing Bcl-2 was cloned. Results: Western blot analysis showed constitutive Bcl-2 expression in HCC-T cells, but not in HepG2 cells. HCC-T was resistant to apoptosis after treatment with an agonist anti-Fas antibody (1 μg/ml for 3 days), whereas 33{\%} of the HepG2 cells were killed by this treatment. Inhibition of Bcl-2 expression by transfection of antisense oligodeoxynucleotides caused spontaneous apoptosis in HCC-T, but not in HepG2 cells, suggesting that Bcl-2 is essential for survival of HCC-T cells, whereas other proteins may substitute for it in HepG2 cells. Following LZBC infection, 10{\%} HepG2 cells were β-galactosidase-positive by X-gal staining and Bcl-2-positive. In cells surviving after anti-Fas treatment, the proportion of β-galactosidase-positive cells increased to 50{\%} and the β- galactosidase activity increased 6-fold, indicating that Bcl-2 expression protected the cells from Fas-mediated apoptosis. In the cloned HepG2 cells stably expressing Bcl-2, the extent of Fas-mediated apoptosis was inversely related to the level of Bcl-2 expression. Conclusion: Bcl-2 confers protection to human hepatoma cells against Fas-mediated apoptosis, and is essential for survival of some, but not all, hepatoma cells.",
keywords = "Antisense oligonucleotide, Gene transfer, Human hepatoma cell line",
author = "Masahiko Takahashi and Hidetsugu Saito and Torayuki Okuyama and Toshiyuki Miyashita and Motomichi Kosuga and Futoshi Sumisa and Masao Yamada and Hirotoshi Ebinuma and Hiromasa Ishii",
year = "1999",
month = "8",
doi = "10.1016/S0168-8278(99)80230-X",
language = "English",
volume = "31",
pages = "315--322",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Overexpression of Bcl-2 protects human hepatoma cells from Fas-antibody- mediated apoptosis

AU - Takahashi, Masahiko

AU - Saito, Hidetsugu

AU - Okuyama, Torayuki

AU - Miyashita, Toshiyuki

AU - Kosuga, Motomichi

AU - Sumisa, Futoshi

AU - Yamada, Masao

AU - Ebinuma, Hirotoshi

AU - Ishii, Hiromasa

PY - 1999/8

Y1 - 1999/8

N2 - Background/Aims: Fas is a cell surface antigen, that triggers apoptosis upon specific ligand or antibody binding. The proto-oncogene bcl-2 prevents apoptosis induced by various treatments. The aim of our study was to evaluate whether Bcl-2 protects hepatoma cells from Fas-mediated apoptosis. Methods: Two human cell lines, HCC-T and HepG2 were used. Expression of Fas antigen and Bcl-2 was detected by flow cytometry and Western blotting. Cell viability and apoptotic change were examined after anti-Fas- and antisense oligodeoxynucleotide treatments. Apoptotic cells were detected by nick-end labelling and the TUNEL method. To test if Bcl-2 expression can protect HepG2 cells from Fas-mediated apoptosis, the cells were transduced using retroviral vector, LZBC, designed to coexpress E. coli β-galactosidase and human Bcl- 2. To further confirm the protective effect of Bcl-2 expression against Fas- mediated apoptosis in HepG2, Bcl-2 expressing plasmid vector was produced and a cell line stably expressing Bcl-2 was cloned. Results: Western blot analysis showed constitutive Bcl-2 expression in HCC-T cells, but not in HepG2 cells. HCC-T was resistant to apoptosis after treatment with an agonist anti-Fas antibody (1 μg/ml for 3 days), whereas 33% of the HepG2 cells were killed by this treatment. Inhibition of Bcl-2 expression by transfection of antisense oligodeoxynucleotides caused spontaneous apoptosis in HCC-T, but not in HepG2 cells, suggesting that Bcl-2 is essential for survival of HCC-T cells, whereas other proteins may substitute for it in HepG2 cells. Following LZBC infection, 10% HepG2 cells were β-galactosidase-positive by X-gal staining and Bcl-2-positive. In cells surviving after anti-Fas treatment, the proportion of β-galactosidase-positive cells increased to 50% and the β- galactosidase activity increased 6-fold, indicating that Bcl-2 expression protected the cells from Fas-mediated apoptosis. In the cloned HepG2 cells stably expressing Bcl-2, the extent of Fas-mediated apoptosis was inversely related to the level of Bcl-2 expression. Conclusion: Bcl-2 confers protection to human hepatoma cells against Fas-mediated apoptosis, and is essential for survival of some, but not all, hepatoma cells.

AB - Background/Aims: Fas is a cell surface antigen, that triggers apoptosis upon specific ligand or antibody binding. The proto-oncogene bcl-2 prevents apoptosis induced by various treatments. The aim of our study was to evaluate whether Bcl-2 protects hepatoma cells from Fas-mediated apoptosis. Methods: Two human cell lines, HCC-T and HepG2 were used. Expression of Fas antigen and Bcl-2 was detected by flow cytometry and Western blotting. Cell viability and apoptotic change were examined after anti-Fas- and antisense oligodeoxynucleotide treatments. Apoptotic cells were detected by nick-end labelling and the TUNEL method. To test if Bcl-2 expression can protect HepG2 cells from Fas-mediated apoptosis, the cells were transduced using retroviral vector, LZBC, designed to coexpress E. coli β-galactosidase and human Bcl- 2. To further confirm the protective effect of Bcl-2 expression against Fas- mediated apoptosis in HepG2, Bcl-2 expressing plasmid vector was produced and a cell line stably expressing Bcl-2 was cloned. Results: Western blot analysis showed constitutive Bcl-2 expression in HCC-T cells, but not in HepG2 cells. HCC-T was resistant to apoptosis after treatment with an agonist anti-Fas antibody (1 μg/ml for 3 days), whereas 33% of the HepG2 cells were killed by this treatment. Inhibition of Bcl-2 expression by transfection of antisense oligodeoxynucleotides caused spontaneous apoptosis in HCC-T, but not in HepG2 cells, suggesting that Bcl-2 is essential for survival of HCC-T cells, whereas other proteins may substitute for it in HepG2 cells. Following LZBC infection, 10% HepG2 cells were β-galactosidase-positive by X-gal staining and Bcl-2-positive. In cells surviving after anti-Fas treatment, the proportion of β-galactosidase-positive cells increased to 50% and the β- galactosidase activity increased 6-fold, indicating that Bcl-2 expression protected the cells from Fas-mediated apoptosis. In the cloned HepG2 cells stably expressing Bcl-2, the extent of Fas-mediated apoptosis was inversely related to the level of Bcl-2 expression. Conclusion: Bcl-2 confers protection to human hepatoma cells against Fas-mediated apoptosis, and is essential for survival of some, but not all, hepatoma cells.

KW - Antisense oligonucleotide

KW - Gene transfer

KW - Human hepatoma cell line

UR - http://www.scopus.com/inward/record.url?scp=0032775972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032775972&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(99)80230-X

DO - 10.1016/S0168-8278(99)80230-X

M3 - Article

C2 - 10453946

AN - SCOPUS:0032775972

VL - 31

SP - 315

EP - 322

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 2

ER -